Clinical trials
Phase 2 Urinary Bladder Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 10 |
| Active, not recruiting | 6 |
| Terminated | 5 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 3 |
| University Health Network, Toronto | 3 |
| Bristol-Myers Squibb | 2 |
| Hoffmann-La Roche | 2 |
| Merck Sharp & Dohme LLC | 2 |
| National Cancer Institute (NCI) | 2 |
| AHS Cancer Control Alberta | 1 |
| Achieve Life Sciences | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Bayer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 41 |
| Carcinoma, Transitional Cell | 7 |
| Ovarian Neoplasms | 6 |
| Breast Neoplasms | 5 |
| Non-Muscle Invasive Bladder Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Esophageal Neoplasms | 4 |
| Pancreatic Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
| Cholangiocarcinoma | 3 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.